CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Lossses)	Treasury Stock
Balance at beginning of period (in shares) at Dec. 31, 2021		48,954,482
Balance at beginning of period at Dec. 31, 2021	$ 325,539	$ 759	$ 653,978	$ 92,111	$ 859	$ (422,168)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	12,074			12,074
Foreign currency translation	243				243
Stock-based compensation (in shares)		277,124
Stock-based compensation	2,277	$ 5	2,272
Stock repurchase (in shares)		(247,174)
Stock repurchase	(8,013)					(8,013)
Common stock dividends	(4,065)			(4,065)
Unrealized gain (loss) on derivative instruments	13,585				13,585
Stock option exercises (in shares)		48,208
Stock option exercises	613		613
Balance at end of period (in shares) at Mar. 31, 2022		49,032,640
Balance at end of period at Mar. 31, 2022	342,253	$ 764	656,863	100,120	14,687	(430,181)
Balance at beginning of period (in shares) at Dec. 31, 2021		48,954,482
Balance at beginning of period at Dec. 31, 2021	325,539	$ 759	653,978	92,111	859	(422,168)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	70,796
Foreign currency translation	(140)
Unrealized gain (loss) on derivative instruments	(8,193)
Balance at end of period (in shares) at Sep. 30, 2022		48,065,277
Balance at end of period at Sep. 30, 2022	360,102	$ 765	662,581	150,943	(7,474)	(446,713)
Balance at beginning of period (in shares) at Mar. 31, 2022		49,032,640
Balance at beginning of period at Mar. 31, 2022	342,253	$ 764	656,863	100,120	14,687	(430,181)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	22,552			22,552
Foreign currency translation	(303)				(303)
Stock-based compensation (in shares)		16,416
Stock-based compensation	2,370		2,370
Stock repurchase (in shares)		(360,659)
Stock repurchase	(5,312)					(5,312)
Common stock dividends	(3,901)			(3,901)
Unrealized gain (loss) on derivative instruments	(19,610)				(19,610)
Stock option exercises (in shares)		12,690
Stock option exercises	122		122
Balance at end of period (in shares) at Jun. 30, 2022		48,701,087
Balance at end of period at Jun. 30, 2022	338,171	$ 764	659,355	118,771	(5,226)	(435,493)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	36,170			36,170
Foreign currency translation	(80)				(80)
Stock-based compensation (in shares)		3,344
Stock-based compensation	2,720		2,720
Stock repurchase (in shares)		(691,844)
Stock repurchase	(11,220)					(11,220)
Common stock dividends	(3,998)			(3,998)
Unrealized gain (loss) on derivative instruments	(2,168)				(2,168)
Stock option exercises (in shares)		52,690
Stock option exercises	507	$ 1	506
Balance at end of period (in shares) at Sep. 30, 2022		48,065,277
Balance at end of period at Sep. 30, 2022	360,102	$ 765	662,581	150,943	(7,474)	(446,713)
Balance at beginning of period (in shares) at Dec. 31, 2022		47,675,796
Balance at beginning of period at Dec. 31, 2022	397,613	$ 766	665,941	188,241	(882)	(456,453)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	51,213			51,213
Foreign currency translation	564				564
Stock-based compensation (in shares)		480,463
Stock-based compensation	2,766	$ 8	2,758
Stock repurchase (in shares)		(540,875)
Stock repurchase	(23,566)					(23,566)
Common stock dividends	(4,055)			(4,055)
Unrealized gain (loss) on derivative instruments	(236)				(236)
Stock option exercises (in shares)		10,683
Stock option exercises	144		144
Balance at end of period (in shares) at Mar. 31, 2023		47,626,067
Balance at end of period at Mar. 31, 2023	424,443	$ 774	668,843	235,399	(554)	(480,019)
Balance at beginning of period (in shares) at Dec. 31, 2022		47,675,796
Balance at beginning of period at Dec. 31, 2022	397,613	$ 766	665,941	188,241	(882)	(456,453)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	180,870
Foreign currency translation	729
Unrealized gain (loss) on derivative instruments	(1,776)
Balance at end of period (in shares) at Sep. 30, 2023		46,297,254
Balance at end of period at Sep. 30, 2023	518,687	$ 774	674,900	357,294	(1,929)	(512,352)
Balance at beginning of period (in shares) at Mar. 31, 2023		47,626,067
Balance at beginning of period at Mar. 31, 2023	424,443	$ 774	668,843	235,399	(554)	(480,019)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	74,328			74,328
Foreign currency translation	502				502
Stock-based compensation (in shares)		24,550
Stock-based compensation	2,915		2,915
Stock repurchase (in shares)		(585,997)
Stock repurchase	(14,330)					(14,330)
Common stock dividends	(3,893)			(3,893)
Unrealized gain (loss) on derivative instruments	(2,952)				(2,952)
Stock option exercises (in shares)		750
Stock option exercises	11		11
Balance at end of period (in shares) at Jun. 30, 2023		47,065,370
Balance at end of period at Jun. 30, 2023	481,024	$ 774	671,769	305,834	(3,004)	(494,349)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	55,329			55,329
Foreign currency translation	(337)				(337)
Stock-based compensation (in shares)		10,829
Stock-based compensation	3,131		3,131
Stock repurchase (in shares)		(778,945)
Stock repurchase	(18,003)					(18,003)
Common stock dividends	(3,869)			(3,869)
Unrealized gain (loss) on derivative instruments	1,412				1,412
Stock option exercises (in shares)
Stock option exercises	0
Balance at end of period (in shares) at Sep. 30, 2023		46,297,254
Balance at end of period at Sep. 30, 2023	$ 518,687	$ 774	$ 674,900	$ 357,294	$ (1,929)	$ (512,352)